Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
1110 Total results for product and free and sample content found
Citeline, Citeline Analytics
By Laura Runkel 08 Nov 2018
For a deeper look into the data behind last year’s completed clinical trials and the trends driving them, Listen to the Completed Clinical Trials 2017: Status Quo or No?
Topic Clinical trials
Trialtrove
By Doro Shin 08 Nov 2018
For a detailed look at the statistics and trends surrounding clinical trials initiated in 2017, we invite you to download 2017 Clinical Trials Roundup: The Evolution Continues. Using a wealth of trial data from Trialtrove, this information-packed white paper provides a detailed analysis of Phase I–III clinical trials that were initiated last year.
Topic Clinical trials
Scrip
06 Nov 2018
November is Men’s Health Awareness Month, and Informa Pharma Intelligence is providing essential insights into drug developments for prostate cancer. Download now for free the "Men's Health: Drug Developments in Prostate Cancer Article Pack", brought to you by Scrip and Pink Sheet.
Citeline
By Pippa Nutkins 05 Nov 2018
Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are. This data-packed whitepaper from Informa Pharma Intelligence can now be downloaded – free.
Medtech Insight
By Amanda Maxwell 31 Oct 2018
Elżbieta Bieńkowska, a European Commissioner, is "realistic and confident" when it comes to the implementation of the new EU medtech regulations. She says everything is going to plan. But that is not what members of the European Parliament are hearing.
Topic Medtech
Scrip
By Kevin Grogan 31 Oct 2018
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
Topic Cancer
Pink Sheet
By Michael Cipriano 31 Oct 2018
If approved, ALKS 5461 would be first opioid-containing product to carry indication for depression; Alkermes CEO Pops tells Pink Sheet that agency's safety and efficacy concerns are surmountable because "all depression drugs have mixed results."
Medtech Insight
By David Filmore 31 Oct 2018
Digital health and innovation strategist John Nosta talks about the need for medical technology companies to stay true to their technology roots and not get too attached to the "patient centricity" bandwagon. Also: innovating organically and "failing smart."
Scrip
By Jessica Merrill 31 Oct 2018
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
Topic Business strategies
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
